Hims & Hers Health Faces Significant Challenges Amid Regulatory Issues
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy HIMS?
Source: Fool
- Significant Stock Decline: Hims & Hers has seen its stock price cut in half year-to-date and down approximately 70% over the past year, reflecting market concerns about its growth prospects, particularly regarding regulatory issues surrounding GLP-1 weight loss drugs.
- Sales Performance Growth: Despite challenges, the company reported a 28% year-over-year increase in fourth-quarter sales to $617.8 million, nearing its guidance range of $605 million to $625 million, demonstrating resilience in its core business.
- User Growth Notable: The number of subscribers grew by 13% to over 2.51 million, with monthly revenue per subscriber increasing by 11% to $83, indicating strong customer preference for its personalized subscription services, which will help stabilize future revenues.
- International Market Potential: The company forecasts revenue between $2.7 billion and $2.9 billion for 2026, with international expansion viewed as a key growth driver, although it faces margin pressure; however, its higher-margin non-weight loss offerings will support overall financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 14.520
Low
16.50
Averages
32.95
High
60.00
Current: 14.520
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Shares Surge on Peptide Approval News
- Peptide Classification Change: Secretary of Health and Human Services Robert F. Kennedy Jr. announced on a podcast that 14 peptides will be moved from the FDA's Category 2 list to Category 1, allowing Hims & Hers to legally produce these compounds, thereby enhancing its market competitiveness.
- Surge in Market Demand: With the legalization of these peptides, Hims & Hers can attract consumers currently purchasing from the grey market, which is expected to significantly increase the company's customer base and sales revenue.
- Strong Stock Performance: Hims & Hers shares rose 7.58% to $15.62 on Monday, with an intraday high of $15.79, reflecting optimistic market sentiment regarding the company's future growth potential.
- Technical Indicator Analysis: Despite the recent price rebound, Hims & Hers stock remains below historical moving averages, currently 17.1% below the 20-day SMA and 64.7% below the 200-day SMA, indicating a long-term downtrend; however, the RSI at 15.87 suggests a potential rebound in the short term.
See More
Investors Discuss Potential PayPal Buyout and Stock Picks
- PayPal Buyout Chatter: Amid a down market, PayPal's stock rose on rumors of potential buyouts, highlighting its appeal as a profitable business, although the market remains cautious about its future trajectory.
- Live Oak Bankshares Performance: The bank's stock has surged nearly 20% over the past year, significantly outperforming the market, showcasing its specialization and high-quality loan origination in the small business lending sector, thereby enhancing its competitive edge.
- Upbound's Value Proposition: Upbound attracts investors with a forward P/E ratio of five and a dividend yield exceeding 7%, and despite slower growth, its revenue accelerated to 11% in the past year, indicating stability and potential in the rental market.
- Disruptive Potential of Hims & Hers: The company challenges traditional healthcare with a direct-to-consumer model, facing legal hurdles but is viewed favorably for its long-term growth potential, which could transform the delivery of healthcare services.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
Novo Nordisk Faces Sales Decline Pressure
- Sales Outlook Decline: Novo Nordisk anticipates adjusted sales to decline by at least 5% and potentially up to 13% this year, indicating severe challenges in a competitive market environment, which has raised investor concerns about its long-term prospects.
- Stock Price Plunge: The stock has lost approximately 60% of its value over the past 12 months, with a current price-to-earnings ratio of just 10, reflecting market pessimism regarding its future growth potential and prompting a sell-off among investors.
- Legal Action Impact: Novo Nordisk has filed a lawsuit against Hims & Hers Health for selling unauthorized versions of its drugs, and if successful, this could help restore sales and improve the company's growth rate, despite the current challenging market conditions.
- Market Opportunities Remain: Despite facing challenges, the GLP-1 drug market is projected to exceed $150 billion by 2035, providing Novo Nordisk with opportunities to maintain a significant presence in this rapidly growing market, especially given the high demand for drug tolerability among users.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
MarketBeat Weekly Recap – February 23 to February 27
Market Trends: Investors are shifting from technology stocks to traditional defensive assets like gold, with evidence suggesting a rotation towards blue-chip stocks as tech stocks remain under pressure.
Earnings Reports: Anticipation surrounds upcoming earnings reports, particularly from companies like NVIDIA and PayPal, with analysts highlighting strong performance expectations and potential growth opportunities.
AI Sector: The AI infrastructure trade continues to be a significant market driver, with investors advised to focus on key stocks within the AI supply chain that are expected to perform well.
Investment Opportunities: Analysts recommend looking for undervalued stocks, particularly in the retail sector, as well as identifying potential long-term opportunities amidst market volatility and recent sell-offs.
See More
Hims & Hers Health Shares Surge on Peptide Approval News
- Peptide Classification Change: Secretary of Health and Human Services Robert F. Kennedy Jr. announced on a podcast that 14 peptides will be moved from the FDA's Category 2 list to Category 1, allowing Hims & Hers to legally produce these compounds, thereby enhancing its market competitiveness.
- Surge in Market Demand: With the legalization of these peptides, Hims & Hers can attract consumers currently purchasing from the grey market, which is expected to significantly increase the company's customer base and sales revenue.
- Strong Stock Performance: Hims & Hers shares rose 7.58% to $15.62 on Monday, with an intraday high of $15.79, reflecting optimistic market sentiment regarding the company's future growth potential.
- Technical Indicator Analysis: Despite the recent price rebound, Hims & Hers stock remains below historical moving averages, currently 17.1% below the 20-day SMA and 64.7% below the 200-day SMA, indicating a long-term downtrend; however, the RSI at 15.87 suggests a potential rebound in the short term.
See More
Investors Discuss Potential PayPal Buyout and Stock Picks
- PayPal Buyout Chatter: Amid a down market, PayPal's stock rose on rumors of potential buyouts, highlighting its appeal as a profitable business, although the market remains cautious about its future trajectory.
- Live Oak Bankshares Performance: The bank's stock has surged nearly 20% over the past year, significantly outperforming the market, showcasing its specialization and high-quality loan origination in the small business lending sector, thereby enhancing its competitive edge.
- Upbound's Value Proposition: Upbound attracts investors with a forward P/E ratio of five and a dividend yield exceeding 7%, and despite slower growth, its revenue accelerated to 11% in the past year, indicating stability and potential in the rental market.
- Disruptive Potential of Hims & Hers: The company challenges traditional healthcare with a direct-to-consumer model, facing legal hurdles but is viewed favorably for its long-term growth potential, which could transform the delivery of healthcare services.
See More
Novo Nordisk Stock Plummets 60% Amidst Concerns
- Stock Price Decline: Novo Nordisk's stock has plummeted approximately 60% over the past year, indicating investor concerns about its long-term prospects, particularly in light of competition from Eli Lilly.
- Sales Guidance Downgrade: The company anticipates a decline in adjusted sales of at least 5%, potentially as much as 13%, which is alarming for growth investors and has contributed to the recent sell-off in its stock.
- Legal Action Impact: Novo Nordisk is suing Hims & Hers Health for selling unauthorized versions of its drugs, and if successful in curbing these sales, it could help stabilize its growth rate this year.
- Market Potential Remains: Despite current challenges, Novo Nordisk remains a significant player in the GLP-1 drug market, which is projected to exceed $150 billion by 2035, suggesting that long-term investors may find the current low price-to-earnings ratio appealing.
See More
Novo Nordisk Faces Sales Decline Pressure
- Sales Outlook Decline: Novo Nordisk anticipates adjusted sales to decline by at least 5% and potentially up to 13% this year, indicating severe challenges in a competitive market environment, which has raised investor concerns about its long-term prospects.
- Stock Price Plunge: The stock has lost approximately 60% of its value over the past 12 months, with a current price-to-earnings ratio of just 10, reflecting market pessimism regarding its future growth potential and prompting a sell-off among investors.
- Legal Action Impact: Novo Nordisk has filed a lawsuit against Hims & Hers Health for selling unauthorized versions of its drugs, and if successful, this could help restore sales and improve the company's growth rate, despite the current challenging market conditions.
- Market Opportunities Remain: Despite facing challenges, the GLP-1 drug market is projected to exceed $150 billion by 2035, providing Novo Nordisk with opportunities to maintain a significant presence in this rapidly growing market, especially given the high demand for drug tolerability among users.
See More
Novo Nordisk Invests €432 Million to Expand Wegovy Production
- Investment Expansion: Novo Nordisk announced a €432 million ($506 million) investment in Ireland to expand production capacity for the Wegovy pill, aiming to meet future global demand, particularly outside the U.S. market.
- Competitive Pressure: This investment follows Novo losing market share to Eli Lilly, with analysts noting that despite competitive pressures, this move demonstrates the company's commitment to the oral medication market, potentially helping to restore market confidence.
- Supply Assurance: Novo has stated that it has resolved supply issues for Wegovy and has enough product to meet U.S. demand; however, challenges remain in meeting global demand, especially as it seeks to launch in other countries.
- Future Outlook: The construction projects in Ireland are set to be completed gradually between 2027 and 2028, expected to include technological upgrades of existing facilities, further enhancing Novo's competitiveness in the obesity drug market, particularly in its strategic focus on oral medications.
See More
MarketBeat Weekly Recap – February 23 to February 27
Market Trends: Investors are shifting from technology stocks to traditional defensive assets like gold, with evidence suggesting a rotation towards blue-chip stocks as tech stocks remain under pressure.
Earnings Reports: Anticipation surrounds upcoming earnings reports, particularly from companies like NVIDIA and PayPal, with analysts highlighting strong performance expectations and potential growth opportunities.
AI Sector: The AI infrastructure trade continues to be a significant market driver, with investors advised to focus on key stocks within the AI supply chain that are expected to perform well.
Investment Opportunities: Analysts recommend looking for undervalued stocks, particularly in the retail sector, as well as identifying potential long-term opportunities amidst market volatility and recent sell-offs.
See More
